Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Rhea-AI Summary

Upstream Bio (Nasdaq: UPB), a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases and severe respiratory disorders, has announced its participation in an upcoming investor event. CEO Rand Sutherland, MD will engage in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025 at 10:30 a.m. ET.

The presentation will be accessible via live webcast in the Events section of the company's investor relations website, with a replay available after the event.

News Market Reaction – UPB

-2.62%

-2.62% Session close to close

In the Sep 9 session, UPB declined 2.62%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025 at 10:30 a.m. ET.

A live webcast of the fireside chat will be available under the Events tab on the Investors section of the Company’s website. A replay will be posted on the Company's website following the presentation.

About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.

Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com

FAQ

When is Upstream Bio (UPB) presenting at the Stifel 2025 Virtual Immunology Forum?

Upstream Bio's CEO will present on September 15, 2025 at 10:30 a.m. ET during a fireside chat at the forum.

How can investors watch Upstream Bio's (UPB) Stifel presentation?

Investors can watch the presentation via live webcast in the Events tab of the Investors section on Upstream Bio's website. A replay will be available after the event.

Who will represent Upstream Bio (UPB) at the Stifel 2025 Virtual Immunology Forum?

Rand Sutherland, MD, the Chief Executive Officer of Upstream Bio, will represent the company at the forum.

What is Upstream Bio's (UPB) main focus as a company?

Upstream Bio is a clinical-stage company developing treatments for inflammatory diseases, with a particular focus on severe respiratory disorders.